BioVie (BioVie) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is BioVie 3-Year Revenue Growth Rate?

BioVie's Revenue per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of BioVie's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, BioVie's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVie's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BioVie's 3-Year Revenue Growth Rate falls into.

BioVie 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

BioVie (NAS:BIVI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

BioVie 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BioVie's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVie (BioVie) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 W Nye Lane, Suite 204, Carson, NV, USA, 89703

Website

https://www.bioviepharma.com

BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Executives

Steve Gorlin	director	150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri	director	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim	officer: Chief Financial Officer	C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo	other: Chief Medical Officer	616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams	officer: EVP Liver Cirrhosis Programs	100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham	officer: EVP Liver Cirrhosis R&D	C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading	officer: EVP Neuroscience R&D	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem	officer: EVP of Product Development	5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch	director	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian	officer: Chief Medical Officer	1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486